Torisel
temsirolimus
Table of contents
Overview
Torisel is a medicine used to treat patients with the following types of cancer:
- advanced renal cell carcinoma (a kidney cancer). ‘Advanced’ means that the cancer has started to spread;
- mantle cell lymphoma (a cancer of B cells, a type of white blood cell). Torisel is used in adults when the lymphoma has come back after previous treatment or if other treatments have not worked.
These diseases are rare, and Torisel was designated an ‘orphan medicine’ (a medicine used in rare diseases) on various dates.
Torisel contains the active substance temsirolimus.
Authorisation details
Product details | |
---|---|
Name |
Torisel
|
Agency product number |
EMEA/H/C/000799
|
Active substance |
Temsirolimus
|
International non-proprietary name (INN) or common name |
temsirolimus
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
L01XE09
|
Publication details | |
---|---|
Marketing-authorisation holder |
Pfizer Europe MA EEIG
|
Revision |
33
|
Date of issue of marketing authorisation valid throughout the European Union |
19/11/2007
|
Contact address |
Boulevard de la Plaine 17 |
Product information
20/06/2022 Torisel - EMEA/H/C/000799 - IB/0087
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antineoplastic agents
Therapeutic indication
Renal-cell carcinoma
Torisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of six prognostic risk factors.
Mantle-cell lymphoma
Torisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (MCL).